A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA) Academic Article uri icon

Overview

MeSH Major

  • Giant Cell Arteritis
  • Immunosuppressive Agents
  • Methotrexate

abstract

  • With this study design, no corticosteroid-sparing benefit could be attributed to the combination of methotrexate with corticosteroid therapy for the treatment of patients with giant cell arteritis. Both groups did well, with few major corticosteroid-related side effects, and most patients were safely tapered off corticosteroids sooner than reported in many series. The shorter overall duration of steroid treatment in this study probably contributed to the remarkably low frequency of side effects, without increased ischemic risk for the patient.

publication date

  • October 4, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11579707

Additional Document Info

start page

  • 495

end page

  • 501

volume

  • 19

number

  • 5